Facebook
Twitter
Telegram
Report an ErrorBioLineRx Ltd. Balance Sheet 2011-2024 | BLRX
Annual Balance Sheet BioLineRx Ltd.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -13.9 M | 704 K | 5.33 M | -4.86 M | -2.13 M | -5.11 M | -5.78 M | -8.87 M | -18.3 M | -8.58 M | ||
Long Term Debt |
- | - | - | 2.74 M | 5.8 M | 7.84 M | 157 K | 250 K | 344 K | - | - | - | 28.9 K |
Long Term Debt Current |
528 K | 427 K | 168 K | 191 K | 202 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 8.22 M | 8.16 M | 1.36 M | 251 K | 552 K | 1.5 M | 5.27 M | 2.91 M | 50.7 K |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
50.7 M | 25.5 M | 13.3 M | 25.3 M | 20.2 M | 14.9 M | 8.08 M | 3.91 M | 3.69 M | 4.4 M | 8.27 M | 9.34 M | 6.81 M |
Deferred Revenue |
- | - | - | 3 K | - | - | - | - | - | - | - | 684 K | - |
Retained Earnings |
- | - | - | -278 M | -248 M | -223 M | -200 M | -175 M | -159 M | -140 M | -145 M | -119 M | -96.7 M |
Total Assets |
63.9 M | 76.4 M | 81.4 M | 47.3 M | 53.6 M | 56.2 M | 61 M | 38.9 M | 51.3 M | 36.2 M | 19.9 M | 24.3 M | 29.3 M |
Cash and Cash Equivalents |
4.26 M | 10.6 M | 13 M | 16.8 M | 5.3 M | 3.4 M | 5.11 M | 2.47 M | 5.54 M | - | - | - | - |
Book Value |
13.2 M | 50.8 M | 68.1 M | 22 M | 33.4 M | 41.3 M | 52.9 M | 35 M | 47.6 M | 31.8 M | 11.7 M | 15 M | 22.5 M |
Total Shareholders Equity |
- | - | - | 22 M | 33.4 M | 41.3 M | 52.9 M | 35 M | 47.6 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet BioLineRx Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 1.73 M | - | 1.7 M | - | 1.66 M | - | 1.63 M | - | 1.76 M | - | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 3.58 M | - | 7.52 M | - | 14.6 M | - | 12 M | - | 8.22 M | - | 11.6 M | - | 8.16 M | - | 689 K | - | 1.36 M | - | - | - | 251 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 13.3 M | - | 17.4 M | - | 25.3 M | - | 23.8 M | - | 20.2 M | - | 20.2 M | - | 14.9 M | - | 6.03 M | - | 8.08 M | - | - | - | 3.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | -305 M | - | -295 M | - | -278 M | - | -261 M | - | -248 M | - | -234 M | - | -223 M | - | -211 M | - | -200 M | - | - | - | -175 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 81.4 M | - | 91.3 M | - | 47.3 M | - | 53 M | - | 53.6 M | - | 62 M | - | 56.2 M | - | 52.2 M | - | 61 M | - | - | - | 38.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 13 M | - | 17.5 M | - | 16.8 M | - | 5.52 M | - | 5.3 M | - | 4.97 M | - | 3.4 M | - | 5.79 M | - | 5.11 M | - | 6.95 M | - | 2.47 M | - | - | - | 5.54 M | - | - | - | 5.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 68.1 M | - | 73.9 M | - | 22 M | - | 29.2 M | - | 33.4 M | - | 41.8 M | - | 41.3 M | - | 46.2 M | - | 52.9 M | - | - | - | 35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 68.1 M | - | 73.9 M | 64.6 M | 22 M | - | 29.2 M | 28.5 M | 33.4 M | - | 41.8 M | 45.9 M | 41.3 M | - | 46.2 M | - | 52.9 M | - | 57.4 M | - | 35 M | - | - | - | 47.6 M | - | - | - | 31.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency